

RETRACTION NOTE OPEN (Interactions with MLKL and CaMKII) Retraction Note to: RIPK3 interactions with MLKL and CaMKII mediate oligodendrocytes death in the developing brain

Yi Qu, Jun Tang, Huiqing Wang, Shiping Li, Fengyan Zhao, Li Zhang, Q. Richard Lu and Dezhi Mu

© The Author(s) 2022

Cell Death and Disease (2022)13:854; https://doi.org/10.1038/s41419-022-05252-3

Retraction to: *Cell Death and Disease* https://doi.org/10.1038/ cddis.2017.54, published online 23 February 2017

The Editors have retracted this article. Concerns have been raised regarding a number of figures, specifically:

- Figure 7a: there appear to be a number of repeating features in the bottom four panels.
- Figure 7b: there appear to be a number of repeating features in the bottom four panels.
- Figure 8b: there appear to be a number of repeating features in the panels for S, HI and RIPK3/Si for MPB(P21).

Additionally, the article shows significant overlap with a previously published article [1]. The Editors therefore no longer has confidence in the reliability of this article.

The authors have not responded to any correspondence from the editor/publisher about this retraction notice.

REFERENCE

 Qu Y, Shi J, Tang Y, Zhao F, Li S, Meng J, et al. MLKL inhibition attenuates hypoxiaischemia induced neuronal damage in developing brain. Exp Neurol. 2016;279:223–31. https://doi.org/10.1016/j.expneurol.2016.03.011.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http:// creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022